24/7 Patient Assistance: 760-405-8205
24/7 Patient Assistance: 760-405-8205
Hospitals & Clinics
specialties & services
Dr. Link graduated from the Keck School of Medicine of USC and completed his residency program at the University of Southern California. He is specialized in Medical Oncology and board certified in Internal Medicine and Oncology. Dr. Link has been in practice for more than 20 years and is affiliated with the Children's Hospital of Orange County and St. Joseph Hospital of Orange. During his career, he has also contributed to several clinical research publications.
Keck School of Medicine of USC
Medical School
University of Southern California - LAC+USC Medical Center
Residency
American Board of Internal Medicine
American Board of Internal Medicine - Oncology
A phase 1, randomized, dose-ranging study of GS-5816, a once-daily NS5A inhibitor, in patients with genotype 1-4 hepatitis C virus.
Lawitz, E.,Freilich, B.,Link, J.,German, P.,Mo, H.,Han, L.,Brainard, D. M.,McNally, J.,Marbury, T.,Rodriguez-Torres, M.; J. Viral Hepat.. 2015 Jul 18.
See more >>
Project Connect Online: Randomized Trial of an Internet-Based Program to Chronicle the Cancer Experience and Facilitate Communication.
Stanton, A. L.,Thompson, E. H.,Crespi, C. M.,Link, J. S.,Waisman, J. R.; J. Clin. Oncol.. 2013 Sep 20.
See more >>
The HCV Non-Nucleoside Inhibitor Tegobuvir Utilizes a Novel Mechanism of Action to Inhibit NS5B Polymerase Function.
Hebner, C. M., Han, B., Brendza, K. M., Nash, M., Sulfab, M., Tian, Y., Hung, M., Fung, W., Vivian, R. W., Trenkle, J., Taylor, J., Bjornson, K., Bondy, S., Liu, X., L...; PLoS ONE. 2012.
See more >>Dr. Link graduated from the Keck School of Medicine of USC and completed his residency program at the University of Southern California. He is specialized in Medical Oncology and board certified in Internal Medicine and Oncology. Dr. Link has been in practice for more than 20 years and is affiliated with the Children's Hospital of Orange County and St. Joseph Hospital of Orange. During his career, he has also contributed to several clinical research publications.
Keck School of Medicine of USC
Medical School
University of Southern California - LAC+USC Medical Center
Residency
American Board of Internal Medicine
American Board of Internal Medicine - Oncology
A phase 1, randomized, dose-ranging study of GS-5816, a once-daily NS5A inhibitor, in patients with genotype 1-4 hepatitis C virus.
Lawitz, E.,Freilich, B.,Link, J.,German, P.,Mo, H.,Han, L.,Brainard, D. M.,McNally, J.,Marbury, T.,Rodriguez-Torres, M.; J. Viral Hepat.. 2015 Jul 18.
See more >>
Project Connect Online: Randomized Trial of an Internet-Based Program to Chronicle the Cancer Experience and Facilitate Communication.
Stanton, A. L.,Thompson, E. H.,Crespi, C. M.,Link, J. S.,Waisman, J. R.; J. Clin. Oncol.. 2013 Sep 20.
See more >>
The HCV Non-Nucleoside Inhibitor Tegobuvir Utilizes a Novel Mechanism of Action to Inhibit NS5B Polymerase Function.
Hebner, C. M., Han, B., Brendza, K. M., Nash, M., Sulfab, M., Tian, Y., Hung, M., Fung, W., Vivian, R. W., Trenkle, J., Taylor, J., Bjornson, K., Bondy, S., Liu, X., L...; PLoS ONE. 2012.
See more >>Do you want to show doctors in your area?
We are sorry but your curent location dosen't have a postal code atached. We cannot display doctors in your area.
